Business Description
Merck & Co Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
MRK.ArgentinaMRK.AustriaMRCK34.BrazilMRK.ChileMRK.France6MK.GermanyMRK.MexicoMRK.PeruMRK.RomaniaMRK.Switzerland0QAH.UKMRK.UkraineMRK.USA Description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.37 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.68 | |||||
| Debt-to-EBITDA | 1.51 | |||||
| Interest Coverage | 25.15 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 4.5 | |||||
| Beneish M-Score | -2.48 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.7 | |||||
| 3-Year EBITDA Growth Rate | 10.5 | |||||
| 3-Year EPS without NRI Growth Rate | 28 | |||||
| 3-Year FCF Growth Rate | 7.1 | |||||
| 3-Year Book Growth Rate | 13.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 10.85 | |||||
| Future 3-5Y Total Revenue Growth Rate | 3.12 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.29 | |||||
| 9-Day RSI | 24.16 | |||||
| 14-Day RSI | 30.84 | |||||
| 6-1 Month Momentum % | 25.58 | |||||
| 12-1 Month Momentum % | 36.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.46 | |||||
| Quick Ratio | 1.22 | |||||
| Cash Ratio | 0.49 | |||||
| Days Inventory | 129.35 | |||||
| Days Sales Outstanding | 57.57 | |||||
| Days Payable | 77.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.7 | |||||
| Dividend Payout Ratio | 0.49 | |||||
| 3-Year Dividend Growth Rate | 9.9 | |||||
| Forward Dividend Yield % | 2.82 | |||||
| 5-Year Yield-on-Cost % | 3.99 | |||||
| 3-Year Average Share Buyback Ratio | 0.8 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 70.63 | |||||
| Operating Margin % | 30.84 | |||||
| Net Margin % | 24.49 | |||||
| ROE % | 35.84 | |||||
| ROA % | 13.96 | |||||
| ROIC % | 21.6 | |||||
| ROC (Joel Greenblatt) % | 82.56 | |||||
| ROCE % | 21.22 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 18.03 | |||||
| Forward PE Ratio | 13.81 | |||||
| PE Ratio without NRI | 18.03 | |||||
| Shiller PE Ratio | 30.53 | |||||
| Price-to-Owner-Earnings | 20.91 | |||||
| PEG Ratio | 2.24 | |||||
| PS Ratio | 4.41 | |||||
| PB Ratio | 5.87 | |||||
| Price-to-Tangible-Book | 135.09 | |||||
| Price-to-Free-Cash-Flow | 17.14 | |||||
| Price-to-Operating-Cash-Flow | 13.27 | |||||
| EV-to-EBIT | 16.34 | |||||
| EV-to-Forward-EBIT | 12.7 | |||||
| EV-to-EBITDA | 13.9 | |||||
| EV-to-Forward-EBITDA | 11.07 | |||||
| EV-to-Revenue | 4.73 | |||||
| EV-to-Forward-Revenue | 4.85 | |||||
| EV-to-FCF | 18.37 | |||||
| Price-to-Projected-FCF | 2.04 | |||||
| Price-to-Median-PS-Value | 1.08 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.55 | |||||
| Price-to-Graham-Number | 10.11 | |||||
| Earnings Yield (Greenblatt) % | 6.12 | |||||
| Forward Rate of Return (Yacktman) % | 14.34 |
